ONCAlert | Upfront Therapy for mRCC
Videos  >  

Selecting I-O Agents and Combinations for Patients With RCC

Robert A. Figlin, MD
Published Online:3:25 PM, Tue November 27, 2018

Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immuno-oncology (I-O) agent for the treatment of patients with renal cell carcinoma (RCC).

As physicians are becoming more comfortable using these agents both alone and in combination with targeted therapies, the key to selecting agents for these patients will vary, Figlin says. Some endpoints to consider may include objective response rate, overall survival, progression-free survival, adverse events, among many others.

The conversations between physicians and patients are different now than they were in the past, Figlin notes. These therapies can not only improve quality of life but also shrink tumors enough that there may be opportunities to go off treatment.

It is an interesting time in the field of RCC, says Figlin, but the challenge lies in selecting I-O agents without comparative trials.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.